SummitTX Capital’s BioNTech BNTX Stock Holding History

SummitTX Capital’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,366	Closed	-$489K	–	762
2025 Q1	$489K	Buy	+5,366	New	+$601K	0.02%	560

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

SummitTX Capital's BNTX Position: Q2 2025 in Review

SummitTX Capital sold out of BioNTech (BNTX) in Q2 2025, closing a stake of 5,366 shares — an estimated $489K sold.

SummitTX Capital first reported a position in BNTX in Q1 2025 and held it in 1 quarter. The position peaked at $489K in Q1 2025. 258 funds tracked by Wall St. Rank hold BNTX as of Q2 2025.

SummitTX Capital reported no remaining BioNTech position as of Q2 2025 after selling out during the quarter.
SummitTX Capital sold 5,366 BioNTech shares in Q2 2025, an estimated $489K.
SummitTX Capital first reported a position in BioNTech in Q1 2025 and held it in 1 quarter.
SummitTX Capital's BioNTech position peaked at $489K in Q1 2025.
258 funds tracked by Wall St. Rank held BioNTech as of Q2 2025.

Based on SummitTX Capital's 13F filing for Q2 2025, filed 14 Aug 2025.